I provide independent and original analysis, pricing metrics and recommendations for the stem, cell, gene and regenerative therapy equities.

RegMed Investors’ (RMi) mid-day analysis, retracing

March 27, 2017

  … As the sector cuts its losses from the downside of the open From five (5) down at the open to twenty eight (28) up of forty-three (43) covered   I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”  

Mesoblast (MESO) hits the skids

March 27, 2017

  Dives -$0.70 or -7.69% in the pre-market after $40 M “raise”  

Bellicum Pharmaceuticals (BLCM) proposes 5M share offering at $12.00 per share

March 22, 2017

  BLCM closed DOWN -$1.47 at $12.90 Thursday, having been UP +$0.46 to $14.37 and is DOWN -$0.16 or -1.24% in the aftermarket    

Roll Call

The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.